Education
About Us
Working with TipRanks
Follow Us
Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
2157 Stock Chart & Stats
HK$4.98
-HK$0.04(-1.65%)
At close: 4:00 PM EST
HK$4.98
-HK$0.04(-1.65%)
Day’s Range― - ―
52-Week RangeHK$2.90 - HK$10.50
Previous CloseN/A
Volume4.02M
Average Volume (3M)13.90M
Market Cap
HK$8.49B
Enterprise ValueHK$7.66B
Total Cash (Recent Filing)HK$536.34M
Total Debt (Recent Filing)HK$917.81M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,804,439,800
10 Day Avg. Volume11,565,494
30 Day Avg. Volume13,902,953
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.92
Price to Sales (P/S)11.31
P/FCF Ratio-16.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthVery strong reported revenue growth indicates rapid top-line expansion and accelerating market adoption of products. Sustained high revenue growth over 2-6 months supports scale advantages, broader customer reach, and greater potential to fund R&D and commercialization investments.
High Gross MarginA high gross margin reflects strong product economics and pricing power in core offerings. With near-80% gross margins, the company can absorb higher operating costs while retaining room to achieve operating profitability if SG&A and R&D are efficiently managed.
Diverse Product PortfolioExposure to oncology, cardiovascular and autoimmune segments plus biologics and diagnostics diversifies revenue streams and reduces single-product concentration risk. Multiple modalities and therapeutic areas support durable commercial channels and partnership opportunities across markets.
Bears Say
Persistent UnprofitabilityConsistent negative net income and negative EBIT/EBITDA margins show the company is not generating operating profits. Over months this reduces retained earnings, limits reinvestment capacity, and increases reliance on external funding unless operating efficiency materially improves.
High LeverageA debt-to-equity ratio around 1.20 and falling equity indicate meaningful leverage, which raises interest and refinancing risk. High leverage constrains financial flexibility, can amplify earnings volatility, and may limit the company's ability to invest in capex or scale manufacturing.
Negative Cash FlowPersistent negative operating and free cash flow means the business does not self-fund growth and likely needs ongoing external financing. Over a multi-month horizon this increases liquidity risk, may dilute shareholders, and constrains timely R&D or commercial expansion.
Lepu Biopharma Co. Ltd. Class H News
2157 FAQ
What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.90 and its highest was HK$10.50 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$8.49B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 40 days.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Aug 20, 2025. The company reported HK$0.022 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.022.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Overvalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.022 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.035%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lepu Biopharma Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.28%
12-Months-Change
Fundamentals
Return on Equity
-21.42%
Trailing 12-Months
Asset Growth
-1.88%
Trailing 12-Months
Company Description
Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
Technical Analysis
Ascletis Pharma, Inc.
―
Keymed Biosciences, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---